Seattle, WA -- (SBWIRE) -- 07/20/2017 -- The report "Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021", This report studies the global sepsis diagnostics market over the forecast period of 2016 to 2021. The market is expected to reach USD 564.1 Million by 2021, at CAGR of 8.8% from 2016 to 2021.

Browse 100 market data Tables and 58 Figures spread through 175 Pages and in-depth TOC on "Sepsis Diagnostics Market"

http://www.marketsandmarkets.com/Market-Reports/sepsis-diagnostic-market-92673155.html

Early buyers will receive 10% customization on reports.

On the basis of products, the global sepsis diagnostics market is segmented into 4 broad categories, namely, blood culture media, assay kits & reagents, instruments, and software. The blood culture media market is estimated to command the largest share of the global sepsis diagnostics market in 2016. The large share of this segment can be attributed to the high use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis. The global assay kits & reagents segment, on the other hand, is expected hold the second largest share in the market owing to the increasing adoption of assay based kits and growing approvals for assay kit products across the globe.

Get The PDF Brochure For This Report@ http://www.marketsandmarkets.com/pdfdownload.asp?id=92673155

Based on technology, the global sepsis diagnostics market is segmented as microbiology, immunoassays, molecular diagnostics, and flow cytometry. The global molecular diagnostic segment is expected to grow at the highest CAGR from 2016 to 2021. Its growth can be attributed to the increasing inclination of physicians and patients towards use of rapid diagnostic products for accurate and quick identification and diagnosis of sepsis. The global sepsis diagnostics market is also divided into two segments by method– conventional diagnostics and automated diagnostics. Furthermore, on the basis of usability, the sepsis diagnostics market is categorized into laboratory testing and point-of-care testing.

Speak to Analyst@ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=92673155

The sepsis diagnostics market on the basis of pathogen is segmented into bacterial sepsis, fungal sepsis, and other infectious pathogens (viral and parasitic infection). The bacterial sepsis segment is expected to account for a larger share (85.7%) of the sepsis diagnostics market in 2016.

Key factors such as rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and growth in the number of product approvals are supporting the growth of this market. On the other hand, lack of standard protocols and awareness and shortage of skilled staff are the major challenges in this market.

As of 2016, North America holds the largest share of the global sepsis diagnostics market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR of 11.9% from 2016 to 2021. A number of factors such as increasing number of surgical procedures, growing number of clinical studies, developing healthcare infrastructure, and rising focus of global players in this region are propelling the growth of the Asia-Pacific sepsis diagnostics market.

bioMérieux SA (France), T2 Biosystems, Inc. (U.S.), Cepheid (U.S.), Thermo Fisher Scientific Inc. (U.S.), Nanosphere, Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Becton, Dickinson and Company (U.S.), Bruker Corporation (U.S.), and Beckman Coulter, Inc. (U.S.) are some of the key players operating in the sepsis diagnostics market.

About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441